Sunday, December 7, 2025 12/7/2025

Center for Research to Optimize Precision Lung Cancer Screening in Diverse Populations

Award Number: UM1CA221939
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/15/2018
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

Center for Research to Optimize Precision Lung Cancer Screening in Diverse Populations - PROJECT SUMMARY / ABSTRACT Lung cancer, the most significant cause of cancer deaths in the US, is an urgent public health threat. It disproportionately affects populations that are already plagued by high poverty rates and low education levels. These populations experience both health disparities in the early diagnosis and treatment of cancer and are historically difficult to reach with cancer screening initiatives. While the results from the National Lung Screening Trial (NLST) indicated that low dose CT (LDCT) is an efficacious and cost-effective strategy for lung cancer screening (LCS), many uncertainties exist with respect to how patient, provider, health system, and societal factors may impact the quality, compliance, effectiveness, and the risk of harms associated with lung cancer screening, within community-based health systems who serve diverse populations. Spanning from Pennsylvania to Hawaii and including five heterogeneous health systems with diverse populations, our proposed PROSPR Research Center, the Center for Research to Optimize Precision Lung Cancer Screening (CPLS), brings together a team of experienced, interdisciplinary researchers and clinicians with long-standing collaborative ties that is well-positioned to pursue research related to the barriers and opportunities associated with the implementation of LCS programs within community settings. The health systems within CPLS include: Henry Ford Health System in Metro Detroit, Kaiser Permanente Colorado, Kaiser Permanente Hawaii, Marshfield Clinic Health System in rural Wisconsin, and University of Pennsylvania Health System. The ultimate goal of CPLS is to identify critical gaps in the LCS process and to design innovative multilevel interventions to reduce lung cancer mortality, particularly among underserved populations. To achieve this goal, CPLS will complete the following specific aims: 1) build a comprehensive data ecosystem by pooling and linking common data elements to capture the entire LCS process and to assess the patient, provider, facility, health system, and societal factors that affect LCS; 2) leverage the CPLS data resource to conduct four high- impact, observational studies of the multilevel factors associated with the LCS process; 3) based on findings from Aims 1 and 2, develop and test interventions to address identifiable gaps in care that may lead to health disparities in LCS, 4) actively participate in Trans-PROSPR research initiatives and collaborate with external investigators via the use of publicly-available CPLS datasets. Our center focuses on the inclusion of diverse, underserved populations that are defined by multiple factors that may adversely impact access to, and utilization of, cancer screening. In response to both the Surgeon General’s strong emphasis on the need to reduce lung cancer mortality and the Cancer Moonshot Blue Ribbon Panel’s focus on reducing the disproportionately high cancer death rates in underserved populations, CPLS will serve as a model for high- impact, translational research to reduce disparities in cancer mortality.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	000	6	3/5/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	000	6	12/14/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $729,340 )
2023	2023	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	001	6	5/2/2023	NON-COMPETING CONTINUATION	$0
2023	2023	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	000	6	4/4/2023	NON-COMPETING CONTINUATION	$729,340
														Subtotal = $729,340

Issue Date FY: 2022 ( Subtotal = $2,777,128 )
2022	2022	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	000	5	3/31/2022	NON-COMPETING CONTINUATION	$2,777,128
														Subtotal = $2,777,128

Issue Date FY: 2021 ( Subtotal = $2,526,598 )
2021	2021	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	002	4	8/27/2021	NON-COMPETING CONTINUATION	$0
2021	2021	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	001	4	4/26/2021	NON-COMPETING CONTINUATION	$0
2021	2021	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	000	4	4/22/2021	NON-COMPETING CONTINUATION	$2,526,598
														Subtotal = $2,526,598

Issue Date FY: 2020 ( Subtotal = $3,084,653 )
2020	2020	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	002	3	4/28/2020	NON-COMPETING CONTINUATION	$0
2020	2020	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	003	3	9/11/2020	NON-COMPETING CONTINUATION	$0
2020	2020	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	001	3	3/20/2020	NON-COMPETING CONTINUATION	$3,084,653
2020	2019	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	000	2	12/2/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $3,084,653

Issue Date FY: 2019 ( Subtotal = $3,089,892 )
2019	2019	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	000	2	3/29/2019	NON-COMPETING CONTINUATION	$3,089,892
2019	2019	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	001	2	7/15/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $3,089,892

Issue Date FY: 2018 ( Subtotal = $3,139,491 )
2018	2018	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cancer Biology Research	000	1	4/13/2018	NEW	$3,139,491
														Subtotal = $3,139,491

Grand Total All Awards = $15,347,102

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Center for Research to Optimize Precision Lung Cancer Screening in Diverse Populations

Award Number: UM1CA221939

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/15/2018

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer